- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable ...

Venus Remedies share price hit an intraday high of Rs 355 per share, rising 6 per cent on the BSE in Monday's intraday trade ...

Pharma company Venus Remedies bagged a Marketing Authorization nod in the Philippines for Pemetrexed 500mg, an agent used in Chemotherapy while treating lung cancer, sending the share price sharply ...

Venus Remedies informed the exchanges on December 6 that it has received the marketing authorisation for Pemetrexed 500mg, a ...